FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.
What happened
FDA reviewed the website all-american-wellness.com in August 2025 and found it offering compounded semaglutide and tirzepatide drug products. The site described them as "Ozempic's compounded version- Semaglutide" and "Mounjaro's compounded version- Tirzepatide." FDA said those statements falsely imply the compounded products are the same as FDA-approved drugs, which they are not, making them misbranded.
What FDA found
Website claims that falsely imply a compounded drug is the same as an FDA-approved drug make the product misbranded.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising or promotion for a compounded drug that is false or misleading in any way makes it misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Shipping misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to stop using the brand-comparison language immediately and to send the Office of Compounding Quality and Compliance a written account of the corrective steps taken, with supporting documents, within 15 working days.
Who should pay attention
- telehealth and online prescriber platforms selling compounded GLP-1 drugs
- compounding pharmacies and the marketing partners that write their website copy
- companies that name a brand drug when describing a compounded alternative
This is a summary. Read the original letter on fda.gov.